Journal of Medical Economics
Volume 27, 2024 - Issue 1
Open access
1,024
Views
0
CrossRef citations to date
0
Altmetric
Oncology
Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK
Grant McCarthya MSD (UK) Ltd, London, UKCorrespondence[email protected]
https://orcid.org/0000-0001-8292-8598
, https://orcid.org/0000-0001-8292-8598
Kate Youngb Merck & Co., Inc, Rahway, NJ, USAhttps://orcid.org/0000-0001-5637-9871
, Matthew Madin-Warburtonc Lumanity, London, UK
, Tyler Mantaiand Lumanity, Las Vegas, NV, USA
, Elizabeth Brookc Lumanity, London, UK
, Kaylie Metcalfec Lumanity, London, UK
, Jan Mikelsone MSD, Zurich, Switzerlandhttps://orcid.org/0000-0001-5233-4756
, Ruifeng Xub Merck & Co., Inc, Rahway, NJ, USA
, Carl Seyla-Hammera MSD (UK) Ltd, London, UK
, Raquel Aguiar-Ibáñezf Merck Canada Inc, Kirkland, QC, Canadahttps://orcid.org/0000-0002-3839-6966
& Mayur Amonkarb Merck & Co., Inc, Rahway, NJ, USA
show all
Pages 279-291
|
Received 21 Nov 2023, Accepted 25 Jan 2024, Published online: 19 Feb 2024
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.